Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Multicenter and Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Recombinant Vaccine (Hansenula Polymorpha) in Chinese Males Aged 18-45 Years

NCT06465914 is registered in ClinicalTrials.gov with Shanghai Bovax Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06465914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06465914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Multicenter and Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Recombinant Vaccine (Hansenula Polymorpha) in Chinese Males Aged 18-45 Years
Lead sponsor
Shanghai Bovax Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 11, 2024
Completion date
July 30, 2030
Enrollment
9,000 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ain1, ain2, ain3, anal cancer, genital wart, hpv-related carcinoma, penile cancer, pin-1, pin2, pin3